TY - JOUR
T1 - A Canadian center's experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities
AU - Chin, Joseph
AU - Cendejas-Gomez, J Jesus
AU - Peters, Max
N1 - Publisher Copyright:
© 2023 Canadian Urological Association.
PY - 2023/8/29
Y1 - 2023/8/29
N2 - Salvage radical prostatectomy for localized radio-recurrent prostate cancer has historically been associated with significant morbidity. Prospectively collected data long-term data on salvage whole-gland cryoablation and, to a lesser extent, high-intensity focused ultrasound (HIFU), have shown they are viable treatment alternatives. This article chronicles the experience (cryoablation, n=187; HIFU, n=81) in a high-volume Canadian center and reviews the literature on other salvage ablative therapies. Whole-gland salvage ablation has yielded oncologic results comparable to those of salvage prostatectomy, with cancer-specific survival and metastatic-free survival of approximately 80%, and biochemical disease-free survival of 35%. Freedom from androgen deprivation therapy was 49% at 12 years. Improved ablative technologies and functional diagnostic imaging modalities have rendered focal salvage ablation feasible in selected patients. Preliminary oncologic and functional results of focal salvage ablation using several new ablative technologies are also reviewed in this article.
AB - Salvage radical prostatectomy for localized radio-recurrent prostate cancer has historically been associated with significant morbidity. Prospectively collected data long-term data on salvage whole-gland cryoablation and, to a lesser extent, high-intensity focused ultrasound (HIFU), have shown they are viable treatment alternatives. This article chronicles the experience (cryoablation, n=187; HIFU, n=81) in a high-volume Canadian center and reviews the literature on other salvage ablative therapies. Whole-gland salvage ablation has yielded oncologic results comparable to those of salvage prostatectomy, with cancer-specific survival and metastatic-free survival of approximately 80%, and biochemical disease-free survival of 35%. Freedom from androgen deprivation therapy was 49% at 12 years. Improved ablative technologies and functional diagnostic imaging modalities have rendered focal salvage ablation feasible in selected patients. Preliminary oncologic and functional results of focal salvage ablation using several new ablative technologies are also reviewed in this article.
UR - http://www.scopus.com/inward/record.url?scp=85173668717&partnerID=8YFLogxK
U2 - 10.5489/cuaj.8331
DO - 10.5489/cuaj.8331
M3 - Review article
C2 - 37787588
SN - 1911-6470
VL - 17
SP - 425
EP - 431
JO - Canadian Urological Association journal = Journal de l'Association des urologues du Canada
JF - Canadian Urological Association journal = Journal de l'Association des urologues du Canada
IS - 12
ER -